Omthera Pharmaceuticals' lead product is an Omega- 3 fatty acid compound called Epanova, originally developed by a Swiss company, Tillotts Pharma AG, as a treatment for Crohn's disease. David Finegold, senior vice president for lifelong learning and strategic growth at Rutgers University, said companies like Omthera, which license drugs already under development, are attractive to investors.
SPOTLIGHT: TECHNOLOGY Enhanced
Pages to are hidden for
"A quick study in uncertain times"Please download to view full document